

**INSIGHTA** ▶

*Saving Lives Through the Power  
of Early Detection*

**Prenetics**™



# Disclaimer

You must read the terms, conditions, limitations, notifications, restrictions, acknowledgments and representations in the following (the “Terms”) before reading or making any other use of this presentation. In reading or making any other use of this presentation, you acknowledge and agree to be bound by the following Terms. This presentation, the materials contained herein, and any further information made available to you, may not be copied, reproduced or redistributed to any other person in any manner or published, in whole or in part, for any purpose, at any time, without the prior written consent of Prenetics Global Limited (the “Company”). This presentation has been prepared by the Company solely for informational purposes and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into investment activity, nor may it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.

This document has been prepared by the Company solely for use in this presentation. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of its affiliates, directors, officers, advisors or representatives will be liable (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising from or in connection with this presentation.

This presentation contains statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this presentation, except as required by law.

# Presentation Participants



**Dennis Lo**  
Chairman of the Board & Co-Founder



**Danny Yeung**  
CEO

# Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US\$200m Joint Venture for Breakthrough Multi-Cancer Early Detection

World Class Science and IPs, led by Professor Dennis Lo, one of the world's most influential and highly respected pioneers in liquid biopsy, considered the father of **Non-Invasive Prenatal Testing**.

Prenetics contribution is **US\$100M in consideration** (US\$80M in cash and US\$20M in Prenetics shares). Capital will be directly used to accelerate clinical trials and commercialization for the **Presight** test, the 1<sup>st</sup> test by Insighta.

Strong and proven management team led by Prenetics CEO – Danny Yeung. Demonstrated history of success.

# Led by Renowned Scientist Prof. Dennis Lo, the Father of Non-Invasive Prenatal Testing (NIPT)



## Prof. Dennis Lo

- Associate Dean (Research) of the Faculty of Medicine of CUHK
  - Director of the Li Ka Shing Institute of Health Sciences, the Li Ka Shing Professor of Medicine and Professor of Chemical Pathology of CUHK
  - Founding Scientific Director of Centre for Novostics, funded by the InnoHK Initiative of the Innovation and Technology Commission of the Hong Kong SAR Government
- 
- Introduced ground breaking NIPT technology in 2011, now screening over 10 million expectant mothers annually across 90+ countries.
  - Global market value of NIPT stands at US\$7.3bn, increasing to US\$13.1bn by 2027.<sup>1</sup>
  - Honored with life sciences most prestigious awards: Fellow of the Royal Society (2011), Royal Medal and Breakthrough Prize (2021), and the distinguished Lasker Award (2022).
  - Co-founded Cirina, acquired by GRAIL for US\$300m in 2017, subsequently purchased by Illumina for US\$7.1bn.
  - Provided intellectual property, R&D leadership, and science oversight for the breakthrough multi-cancer early detection technology "Fragma," published in 2022<sup>2</sup>.

1. <https://www.annualreviews.org/doi/10.1146/annurev-genom-083118-015053>  
2. <https://www.pnas.org/doi/10.1073/pnas.2209852119>

# INSIGHTA Board of Directors



**Prof. Dennis Lo**  
Chairman of the  
Board & Co-Founder



**Danny Yeung**  
CEO



**Anand Madduri**  
Founder and CIO of  
ApaH Capital



**Prof. Allen Chan**  
Co-Founder



**Ben Cheng**  
MD of C Capital



**Prof. Tony Mok**  
Chairman, Dept of  
Clinical Oncology;  
Li Shu Fan Prof. of  
Oncology CUHK




A photograph of a man with dark hair and a beard, wearing a grey sweater and a green scarf, carrying a young child on his shoulders. Both are smiling and looking towards the right. The background is a soft-focus outdoor setting with green foliage and sunlight filtering through the trees.

# INSIGHTA ▶

Our breakthrough technology detects cancers at the early stages, significantly improving the chances of treatment and ultimately saving lives.


# Cancer Kills 10M People Worldwide Annually





# Early Detection Provides Patients with the Best Possible Outcomes and in Saving Lives

5-Year global survival rate at various stages of diagnosis



- Ovarian Cancer
- Pancreatic Cancer
- Lung Cancer
- Prostate Cancer
- Liver Cancer

89%  
Survival

High 5-year cancer-specific survival when diagnosed early

21%  
Survival

Low 5-year cancer-specific survival when diagnosed late

# Early Detection Can Potentially Benefit 1 billion+ People. Annually.

Population Group	Estimated Number of People (as of 2021)
Total global population	7.8 billion
People age of 40+ globally	2.03 billion
Total population in Asia	4.7 billion
People age of 40+ in Asia	1.22 billion
Total population in China	1.41 billion
People age of 40+ in China	366 million

Note: the median age of cancer diagnosis is 66 years of age according to data from the American Cancer Society. This suggests that the population most likely to benefit from early detection is aged 40 and above

# Lung Cancer, #1 Deadliest Cancer in China

## High Incidence

- ~ 135 million people at-risk, whom are aged 50-80 with smoking history
- ~ 900,000 lung cancer cases diagnosed in China in 2019

## High Mortalities and Late Detection

- ~47% of diagnosed cases of lung cancer are in stage 3 and 4 with 6% survival rate
- Only ~23% of diagnosed cases of lung cancer are in stage 1 and 2
- Lung cancer was by far the most lethal cancer type in China, killing more than 700,000 people in 2020

## Current Screening is Unsatisfactory

- Current globally-accepted guidelines recommend annual low-dose helical CT scan screening for high-risk individuals
- Low ~0.4% screening rate for lung cancer in China

Note: population and prevalence data based on multiple sources including from WHO, IARC, WCLC, national health departments and industries, and research institutions

# Liver Cancer, the 2<sup>nd</sup> Deadliest Cancer in China

## High Incidence

- ~ 85 million people living with chronic hepatitis B infection
- ~ 404,000 newly diagnosed cases of liver cancer in China in 2020


## High Mortalities and Late Detection

- ~ 56% of diagnosed cases of liver cancer are in stages 3 and 4
- Only ~ 17.5 % of diagnosed cases of liver cancer are in stage 1
- ~ 372,000 deaths of liver cancer in China in 2020

## Current Screening is Unsatisfactory

- Ultrasound, AFP and CT is current standard of care for liver cancer diagnosis
- Sensitivity ranges between ~ 45% for Ultrasound and ~ 63% for ultrasound + AFP

# At-Risk Liver and Lung Cancer Population in Asia is 400M Compared to 24M in USA



Note: population and prevalence data based on multiple sources including from WHO, IARC, national health departments and industries, and research institutions

# The Science



# Transforming Early Detection with World-Class Science

Take 2™

+

INSIGHTA



ctDNA –  
EB DNA


cf-DNA –  
FRAGMA

Prospective  
20,174  
Clinical Trial

Development  
& Validation


87 Patent  
families

690+ Publications



Led by Prof. Dennis Lo and Prof. Allen Chan, pioneers in liquid biopsy.

# Large-scale Proven Accuracy for Liquid Biopsy for Nasopharyngeal Cancer Screening



**97.1%**

**SENSITIVITY**

**98.6%**

**SPECIFICITY**

**Table 2. Sensitivity and Specificity of the Two-Stage Screening Protocol for the Detection of Nasopharyngeal Carcinoma.\***

Finding	Screen-Positive (N = 308) <sup>†</sup>	Screen-Negative (N = 19,865)
Confirmed nasopharyngeal carcinoma by the screening protocol or nasopharyngeal carcinoma reported to have developed within 1 yr — no.	34	1
No nasopharyngeal carcinoma within 1 yr after screening — no.	274	19,864
Sensitivity — % (95% CI)	97.1 (95.5–98.7)	
Specificity — % (95% CI)	98.6 (98.6–98.7)	
Positive predictive value — % (95% CI)	11.0 (10.7–11.3)	
Negative predictive value — % (95% CI)	99.995 (99.99–100.00)	
Proportion of stage I/II disease in the 34 cases of nasopharyngeal carcinoma identified by screening — % (95% CI)	70.6 (69.6–72.5)	

Source: <https://www.nejm.org/doi/full/10.1056/nejmoa1701717>





# Quantum Leap FRAGMA Liquid Biopsy Platform

## Proprietary cfDNA technology

Epigenetics is the modification of DNA that affect its behavior without changing the DNA sequence.

Fragmentation pattern of plasma DNA can be used as an epigenetics-based multi-cancer test.







## Background

The detection of methylation aberrations in plasma DNA provides a non-invasive means for the detection of a wide variety of cancers. FRAGMA is a new technology which allows the determination of DNA methylation status without the use of bisulfite treatment, enzymatic conversion or 3<sup>rd</sup> generation sequencing.

# Applications of FRAGMA for Liver Cancer (HCC)




- 20 patients had early-stage HCC
- 7 patients had intermediate stage HCC




- 7 patients had advanced HCC
- 38 healthy subjects and 17 hepatitis B carriers


# Applications of FRAGMA for Colorectal Cancer




- 11 patients had colorectal cancer
- 8 healthy subjects



# Applications of FRAGMA for Lung Cancer




- 10 patients had lung cancer
- 8 healthy subjects




Source: <https://www.pnas.org/doi/10.1073/pnas.2209852119>

# Applications of FRAGMA for Bladder Cancer by Urine



- 19 low grade non-muscle invasive bladder cancer
- 18 high grade non-muscle invasive bladder cancer
- 9 muscle invasive bladder cancer



# Summary of FRAGMA Technology

FRAGMA provides an accurate and low cost method for studying the genomewide methylation profile of circulating DNA.

As DNA methylation changes are hallmarks for a wide variety of cancers, this can be potentially applied to a multi-cancer early detection test.

- 1 Accurate and early detection of HCC (Liver Cancer) with shallow-depth sequencing
- 2 Initial studies has also shown it is applicable for **early detection** for lung and colorectal cancer
- 3 Urine DNA has shown to be valuable for the **early detection** of urogenital cancers
- 4 **Versatile technology** can be potentially applied to a Multi-cancer early detection test
- 5 **Low cost**, enabling accessibility of early detection cancer to a much wider population than current testing methods

Introducing  
Presight.  
Our 1<sup>st</sup> Test






# Presight Liver Cancer Trial Details



# Strong Product Pipeline Backed by World-Class Science

Product	Indication	Early Stage Development	Case Control Study	Prospective Trial	Regulatory Approval
Presight Liver	Liver Cancer Screening				
Presight Bladder	Bladder Cancer Screening				
Presight Lung	Lung Cancer Screening				
Presight One MCED	10+ Multi-Cancer Screening				

# Key Commercial Roadmap for the Next 5 Years



# A US\$6B Screening Opportunity in 2030 in Asia. Annually.

Presight  
Liver

Liver Cancer  
Screening

Presight  
Bladder

Bladder Cancer  
Screening

Presight  
Lung

Lung Cancer  
Screening

Presight One  
MCED

10+ Multi-Cancer  
Screening



## US\$6B sales potential in 2030 with robust margins

- ✓ 30m+ annual test population in liver and lung cancer (400m at-risk)
- ✓ Additional cancers and MCED creates further upside
- ✓ Targeting 70% gross margins at scale



## High sensitivity and low cost screening test


- ✓ Target of 90% or greater sensitivity
- ✓ Target of less than US\$200 for end user price



## US\$80M cash

- ✓ Strong cash position allows ability to fund clinical trials without further funding
- ✓ Allows for commercialization
- ✓ Cash also allows research and development of new technologies, and generation of IPs

# By year 2035, Global NGS Oncology Testing Market is Expected to Reach **US\$75 Billion**



**75%**  
CAGR

**Screening (~150 Million Tests)**

Asymptomatic population at heightened risks

**16%**  
CAGR

**Therapy Selection (~7 Million Tests)**

Population diagnosed with cancer

**27%**  
CAGR

**Monitoring (~20 Million Tests)**

Population monitored for therapeutic response or disease recurrence

# The Transaction



# Transaction Summary

## Terms

- Acquisition of 50% of the equity interests in Insighta for total consideration of US\$100M, with US\$80M in cash and US\$20M of shares in Prenetics
- Prof. Dennis Lo to be Chairman of Insighta
- Danny Yeung as CEO of Prenetics and of Insighta

## Timing and Closing

- Anticipated to close in July 2023
- Subject to customary closing conditions and regulatory approvals

# Prenetics™

Enhancing Life through Science

## Prevention

Fast-growing health-conscious consumer base

 Circle DNA

## Early Detection

Detecting multi-cancer at the early stages, significantly improving the chances of treatment

 INSIGHTA

## Treatment

Targeted therapy for cancer patients

 ACT GENOMICS



# Prevention | CircleDNA

At CircleDNA, we recognize that every individual has unique health needs and goals, and we are dedicated to empowering them with the tools and knowledge to take control of their health.




# Treatment | ACT Genomics

## Traditional Medicine: Same Treatment for all

Cancer patient with i.e. colon cancer receive the same therapy, even though they have different biomarkers.

### Traditional Medicine



## Innovative Medicine: Personalized Medicine

Cancer patient with i.e. colon cancer receive personalized therapy based on their biomarkers.

### ACT Genomics

